These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 34633645)

  • 21. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.
    Declercq J; Van Damme KFA; De Leeuw E; Maes B; Bosteels C; Tavernier SJ; De Buyser S; Colman R; Hites M; Verschelden G; Fivez T; Moerman F; Demedts IK; Dauby N; De Schryver N; Govaerts E; Vandecasteele SJ; Van Laethem J; Anguille S; van der Hilst J; Misset B; Slabbynck H; Wittebole X; Liénart F; Legrand C; Buyse M; Stevens D; Bauters F; Seys LJM; Aegerter H; Smole U; Bosteels V; Hoste L; Naesens L; Haerynck F; Vandekerckhove L; Depuydt P; van Braeckel E; Rottey S; Peene I; Van Der Straeten C; Hulstaert F; Lambrecht BN
    Lancet Respir Med; 2021 Dec; 9(12):1427-1438. PubMed ID: 34756178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis.
    Kyriakopoulos C; Ntritsos G; Gogali A; Milionis H; Evangelou E; Kostikas K
    Respirology; 2021 Nov; 26(11):1027-1040. PubMed ID: 34605114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of dexamethasone in patients with ARDS and COVID-19 - prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial.
    Maláska J; Stašek J; Duška F; Balík M; Máca J; Hruda J; Vymazal T; Klementová O; Zatloukal J; Gabrhelík T; Novotný P; Demlová R; Kubátová J; Vinklerová J; Svobodník A; Kratochvíl M; Klučka J; Gál R; Singer M;
    Trials; 2021 Mar; 22(1):172. PubMed ID: 33648568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial.
    Malekzadeh R; Abedini A; Mohsenpour B; Sharifipour E; Ghasemian R; Javad-Mousavi SA; Khodashahi R; Darban M; Kalantari S; Abdollahi N; Salehi MR; Rezaei Hosseinabadi A; Khorvash F; Valizadeh M; Dastan F; Yousefian S; Hosseini H; Anjidani N; Tabarsi P
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107102. PubMed ID: 33075713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tocilizumab in the Management of COVID-19: A Preliminary Report.
    Li M; Yoo EJ; Baram M; McArthur M; Skeehan C; Awsare B; George G; Summer R; Zurlo J; Jallo J; Roman J
    Am J Med Sci; 2021 Feb; 361(2):208-215. PubMed ID: 33358502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of the effectiveness of different doses of tocilizumab and sarilumab in the treatment of severe COVID-19: a natural experiment due to drug shortages.
    Swets MC; Moss RJ; Kor F; Hilarius D; Moes DJAR; Berkhout WE; van den Toorn LM; van den Oever NCG; de Valk R; Rosendaal FR; Hunfeld N; Groeneveld GH; de Boer MGJ
    Int J Infect Dis; 2023 Apr; 129():57-62. PubMed ID: 36738957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ninety-day outcome of patients with severe COVID-19 treated with tocilizumab - a single centre cohort study.
    Sava M; Sommer G; Daikeler T; Woischnig AK; Martinez AE; Leuzinger K; Hirsch HH; Erlanger T; Wiencierz A; Bassetti S; Tamm M; Tschudin-Sutter S; Stoeckle M; Pargger H; Siegemund M; Boss R; Zimmer G; Vu DL; Kaiser L; Dell-Kuster S; Weisser M; Battegay M; Hostettler K; Khanna N
    Swiss Med Wkly; 2021 Aug; 151():w20550. PubMed ID: 34375986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19).
    Urwyler P; Charitos P; Moser S; Heijnen IAFM; Trendelenburg M; Thoma R; Sumer J; Camacho-Ortiz A; Bacci MR; Huber LC; Stüssi-Helbling M; Albrich WC; Sendi P; Osthoff M
    Trials; 2021 Jan; 22(1):1. PubMed ID: 33397449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nebulised surfactant for the treatment of severe COVID-19 in adults (COV-Surf): A structured summary of a study protocol for a randomized controlled trial.
    Dushianthan A; Clark H; Madsen J; Mogg R; Matthews L; Berry L; de la Serna JB; Batchelor J; Brealey D; Hussell T; Porter J; Djukanovic R; Feelisch M; Postle A; Grocott MPW
    Trials; 2020 Dec; 21(1):1014. PubMed ID: 33302976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of poor outcome in tocilizumab treated patients with Sars-CoV-2 related severe respiratory failure: A multicentre real world study.
    Masotti L; Landini G; Panigada G; Grifoni E; Tarquini R; Cei F; Cimolato BMA; Vannucchi V; Di Pietro M; Piani F; Fortini A; Faraone A; Nenci G; Cipollini F; Blanc P; Lotti P; Di Natale M; Risaliti F; Aquilini D; Seravalle C; Bribani A; Farsi A; Micheletti I; Cioni E; Pelagalli G; Mattaliano C; Pinto G; Madonia EM; Sivieri I; Mannini M; Valoriani A; Brancati S; Rosselli M; Pavone E; Burla MC; Sergi A;
    Int Immunopharmacol; 2022 Jun; 107():108709. PubMed ID: 35334359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The association between tocilizumab therapy and the development of thrombosis in critically ill patients with COVID-19: a multicenter, cohort study.
    Aljuhani O; Al Sulaiman K; Korayem GB; Altebainawi AF; Alsohimi S; Alqahtani R; Alfaifi S; Alharbi A; AlKhayrat A; Hattan A; Albassam M; Almohammed OA; Alkeraidees A; Alonazi DA; Alsalman WF; Aldamegh G; Alshahrani R; Vishwakarma R
    Sci Rep; 2024 Feb; 14(1):3037. PubMed ID: 38321099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimising the dose of clonidine to achieve sedation in intensive care unit patients with population pharmacokinetics.
    Cloesmeijer ME; van den Oever HLA; Mathôt RAA; Zeeman M; Kruisdijk-Gerritsen A; Bles CMA; Nassikovker P; de Meijer AR; van Steveninck FL; Arbouw MEL
    Br J Clin Pharmacol; 2020 Aug; 86(8):1620-1631. PubMed ID: 32150285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update.
    Tleyjeh IM; Kashour Z; Riaz M; Hassett L; Veiga VC; Kashour T
    Clin Microbiol Infect; 2021 Aug; 27(8):1076-1082. PubMed ID: 33915284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
    Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
    J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single versus multiple doses of Tocilizumab in critically ill patients with coronavirus disease 2019 (COVID-19): A two-center, retrospective cohort study.
    Al Sulaiman K; Aljuhani O; Bin Salah K; Korayem GB; Eljaaly K; Al Essa M; Kharbosh A; Al Harbi F; Abuzaid M; Al Bilal S; Almagthali A; Alsohemi S; Alshabasy A; Noureldeen H; Aboudeif M; Alshehri A; Vishwakarma R
    J Crit Care; 2021 Dec; 66():44-51. PubMed ID: 34438133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia.
    Cardona-Pascual I; Berlana D; Martinez-Valle F; Campany-Herrero D; Montoro-Ronsano JB
    Med Clin (Barc); 2022 Apr; 158(7):301-307. PubMed ID: 34147248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical presentation of secondary infectious complications in COVID-19 patients in intensive care unit treated with tocilizumab or standard of care.
    Taramasso L; Magnasco L; Portunato F; Briano F; Vena A; Giacobbe DR; Dentone C; Robba C; Ball L; Loconte M; Patroniti N; Frisoni P; D'Angelo R; Dettori S; Mikulska M; Pelosi P; Bassetti M
    Eur J Intern Med; 2021 Dec; 94():39-44. PubMed ID: 34511338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant Tocilizumab in the Treatment of Patients with Moderate to Severe COVID-19 Pneumonia: An Observational Study.
    Shastri M; Raval DM; Rathod VM; Patel D
    J Assoc Physicians India; 2022 Jan; 70(1):11-12. PubMed ID: 35062798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pooled Population Pharmacokinetic Analysis and Dose Recommendations for Ciprofloxacin in Intensive Care Unit Patients with Obesity.
    van Rhee KP; Brüggemann RJM; Roberts JA; Sjövall F; van Hest RM; Elbers PWG; Abdulla A; van der Linden PD; Knibbe CAJ
    J Clin Pharmacol; 2024 Sep; 64(9):1165-1172. PubMed ID: 38736038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.